Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

How to Use CBD Oil to Fully Reap Its Benefits

liposoluble components are Cannabinoids



  • liposoluble components are Cannabinoids
  • Chemical Components of Cannabis
  • Introduction
  • A cannabinoid is one of a class of diverse chemical compounds that acts on cannabinoid . Tetrahydrocannabinol. Tetrahydrocannabinol (THC) is the primary psychoactive component of the Cannabis plant. . This is because they are fat-soluble, lipophilic molecules that accumulate in fatty tissues. Research shows the. Apr 19, They are considered to be liposoluble molecules classified Like many other components of cannabis, CBN is rejected by water, as it is only. Jul 3, Cannabinoids (CBD, THC, etc.) are hydrophobic (water-hating) oily substances and, as such, not water-soluble. They can, however, be.

    liposoluble components are Cannabinoids

    In this sense the presence of CBN in cannabis is usually associated with the aging of the plant: One of the characteristics of CBN is that it is contains psychoactive components, but they are between 8 and 10 times less strong than in THC , so its effects are attenuated. Several studies have investigated its effects on mice and pigeons comparing it with the effect of THC [1].

    Thus, it has been found that one of the most important benefits of cannabinol are the relaxing effects when doses much more potent than THC are delivered. Other studies have also detected particularly sedative side effects of CBN, which could improve sleep quality.

    Combined with different terpenes hydrocarbon compounds produced by several plants , CBN has analgesic, anti-insomnia, anti-convulsive and anxiolytic properties, among others. Other studies have also observed anti-bacteriological , anti-inflammatory and appetite stimulant effects. These can be anionic, cationic, nonionic, and zwitterionic.

    Surfactants that should not be used in assembly of nanoparticle compositions of this disclosure include ionic, synthetic, and polymer surfactants recognized as toxic and irritants. The phospholipids present in liquid lecithin phosphatidylcholine. Their surface-active simultaneous hydrophilic and hydrophobic properties enable lecithin to make stable blends of biomaterials that otherwise do not mix.

    Lecithins can provide fast, complete wetting of powders into aqueous systems. They are non-ionic liquids used as surfactants for dispersing hydrophobic particles in aqueous solutions ion the assembly of lipid nanoparticles of this disclosure.

    Polysorbate 80 is a polyethylene sorbitol ester, also known as Tween 80, sorbitan monooleate, polyoxyethylenesorbitan monooleate is used for emulsifying and dispersing substances. Polysorbate 20 is a polyoxyethylene sorbitol ester member of the polysorbate family used as emulsifying agents for the preparation of stable oil-in-water emulsions. They include lecithins such as Alcolec S, Alcolec BS and Alcolec XTRA-A, polysorbates such as Polysorbate 80 and Polysorbate 20, monoglycerides, diglycerides, triglycerides, glyceryl monoleate, polysorbates polaxamers and other non-toxic ionic and ionic surfactants that are known to the art.

    Surfactants may be selected to provide coatings and functional groups on the nanoparticle membrane and alter the membrane surface charge for greater transport of cannabinoids across cell membranes, binding to receptor sites and signal transduction. These lipids include fatty acids such stearic acid, palmitic acid, belenic acid, myrisitic acid and oleic acid; free fatty acid alcohols such as stearyl alcohol, cetyl alcohol, myristyl alcohol, lauryl alcohol; triglycerides such as trimyristin, tripalmitin, trilaurin; waxes such as bees wax, cetyl palmitate, carnuba wax, cannabis wax extract; mono, di and triglycerides mixtures such as Suppocire NC, witepsol bases, glyceryl monostearate, glyceryl behenate, palmitostearate, and softisan; and others such as cacao butter, castor oil, anhydrous milk fat, and hydrogenated palm oil.

    Preferred surfactants in nanoparticles of this disclosure should be biocompatible, biodegradable GRAS listed and non-toxic as nanoparticles. Suitable carrier fluids and solvents include water, sterile saline, glycerides glycerine, and ethanol, sorbitol, lipids, fatty acids, glycine, and silicone oils; and their dispersions emulsions, suspensions, mixtures, self- assembly and other methods of incorporation in the assembly of nanoparticles. Suitable carrier fluids and solvents should be GRAS listed, biocompatible, biodegradable and non-toxic as nanoparticles.

    Plus, preservatives should be selected that do not induce changes in barrier functions, do not induce toxic and allergic effects, do not induce adverse effects to the nanoparticles, and do not induce adverse effects to the transported cannabinoids. Some of the preservatives for consideration in use include tocopherols, ascorbyl palmitate, sorbates, parabens, optiphen, thimersal, benzoic acid, benzalkonium chloride, benzehtkonium chloride polyquaternium- 1 , ethyl lauroyl arginate, and rosemary oleoresin, Jeecide and Optiphen.

    Preferred preservatives in phospholipid nanoparticles of this disclosure should be. Preferred preservatives should not interfere with the delivery of the cannabinoids.

    Nanoparticles with 50 nm show the most efficiency of uptake. These results in greater cannabinoid bioactivity in therapy and fewer adverse effects compared to administration of raw and non-encapsulated cannabinoids.

    The sweeteners used may be natural sweeteners or artificial sweeteners. Natural sweeteners include Stevia extract Steviol Glycosides, xylitol, sucrose, fructose,.

    Examples of artificial sweeteners include sucralose, aspartame, acesulfame K, neohesperidine, dihydrochalcone, thaumatin, saccharin and saccharin salts. Preferred sweeteners for this disclosure should be sucralose, Acesulfame K and natural sweeteners such such as steviol glycosides, xylitol, erythritol and thaumatin.

    Preferred sweeteners in nanoparticles of this disclosure should be biocompatible, GRAS listed and nontoxic as nanoparticles. The flavors used may be natural sweeteners or artificial sweeteners. Examples of flavoring agents useful in the compositions of the invention include fruit e. Typically the sweetener content will be about 0.

    The actual increase amount depends on the molecular characteristics of the cannabinoid, the encapsulation characteristics into phospholipid nanoparticles, the structural characteristic of the phospholipid nanoparticles, the method and vehicles of administration and metabolic difference between users. The dose reduction can range from a 2-fold reduction in mg dose to an 8-fold reduction in mg dose.

    Preferably, the range is from about a 2-fold reduction to about an 8-fold reduction in mg cannabinoid dose. These techniques can be performed in this sequential order or may be performed sequentially in alternate orders.

    They represent an alternative class of vehicles to liposomes, emulsions, aqueous solutions, vaporizing, smoking, transdermal patches, chewing gums, edible food forms and solid formed tablets and capsules to for cannabinoid therapy.

    The preferred method is a. Methods suitable for administering a composition to the nasal cavity will be well known by the person of ordinary skill in the art. Any suitable method may be used. The preferred method of administration is the use of a pump device. The liquid nanosphere gel is administered under the tongue for transport directly into the blood stream. Sublingual drug solutes are rapidly absorbed into the reticulated vein, which lies underneath the oral mucosa, and transported through the facial veins, internal jugular vein, andbraciocephalic vein and then drained in to systemic circulation.

    Procedure for a In sequence, pre-nanoparticle blend is ground through a product mill for particle size reduction, at 10, RPM for 10 minutes with an Ultra-Turrax. Next, 20 mg of potassium sorbate preservative, mg of flavor oil and 50 mg of steviol glycoside sweetener is thoroughly dispersed into the composition.

    Composition is administered to the sublingual mucosa by a precision liquid pump device bottle that delivers mcl per pump. Each pump dose contains 30mg of CBD and 1. Heat this vessel to C. Next, discharge mg of water heated to C into the vessel from a separate heated vessel. Stir this vessel containing pre-nanoparticle blend for 5 minutes.

    In sequence, pre-nanoparticle blend is ground through a product mill for particle size reduction, homogenate at 10, RPM for 10 minutes with a Ultra- Turrax homogenizer under cooling, and processed in an ultrasonification system for 40 minutes with watts of power in a flow through chamber under cooling to form the phospholipid nanoparticle cannabinoid composition.

    Discharge mg of ethanol into a vessel containing the blend stirring at RPM. Next discharge mg of Xanthum gum into a vessel containing the blend stirring at RPM. Follow by discharging 33mg of potassium sorbate preservative in the vessel and stir for 5 minutes. The NanoSphere Gel composition is administered topically to skin by precision liquid pump device bottle that delivers mcl per pump. Each pump contains 50 mg of CPD and 2. Procedure for a 1: Follow by discharging mg of polysorbate 80 into the blend.

    In sequence, pre-nanoparticle blend is ground through a product mill for particle size reduction, homogenate at 10, RPM for 10 minutes with an Ultra- Turrax homogenizer under cooling, and processed in an ultrasonification system for 35 minutes with watts of power in a flow through chamber under cooling to form the phospholipid nanoparticle cannabinoid composition.

    Next discharge mg of distilled water and 4 mg of ethanol into phospholipid nanoparticle cannabinoid composition while stirring at 10, RPM for 10 minutes. Next discharge 35 mg monobasic potassium phosphate and 34 mg of dibasic potassium phosphate in to the composition while stirring at rpm.

    Follow by discharging 75 mg of sodium chloride, 30 mg of EDTA sodium and 1. Composition is administered to nasal mucosa by precision liquid pump device bottle that delivers 75 mcl per pump. Each pump dose contains 7. Procedure for 30mg of CBD and 1. Stir until completely dispersed. The dosage is mcl. The NanoSphere gel composition is administered to the sublingual mucosa by a precision liquid pump device bottle that delivers mcl per pump.

    Each pump intraorally delivers a standardized precision-metered dose of 30mg of CBD and 1. Procedure for 35 mg of CBD of hempseed oil cannabinoid extract in phospholipid nanoparticles for intraoral delivery. The he dosage is mcl. The Nanosphere gel composition is administered to the sublingual mucosa by a precision liquid pump device bottle that delivers mcl per pump.

    NanoSphere phospholipid nanoparticle viscoelstic gel into the systemic circulation. Procedure for 25 mg THC and 5 mg CBD cannabis oil cannabinoid extract in phospholipid nanoparticles for intraoral delivery. Each pump intraorally delivers a standardized precision-metered dose of 25mg of THC and 1. CBD into the heated vessel.

    Disperse 24 gm of soya lecithin Alcolec LPH 20 and The NanoSphere Gel composition is administered to nasal mucosa by precision liquid pump device bottle that delivers mcl per pump.

    Each pump delivers a standardized precision- metered dose of 7. Procedure for 50 mg of CBD and 2. Disperse gm polysorbate 80 into the vessel followed by 2, gm of water mixed with 2, Follow by discharging Each pump delivers a standardized precision-metered dose of 50 mg of CBD and 2.

    It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar structures. The present disclosure includes any and all embodiments of the following claims.

    Such changes are also implicitly included in the description. They still fall within the scope of this disclosure. It should be understood that this disclosure is intended to yield a patent covering numerous aspects of the disclosure both independently and as an overall system and in both method and apparatus modes. Further, each of the various elements of the disclosure and claims may also be achieved in a variety of manners.

    This disclosure should be understood to encompass each such variation, be it a variation of an embodiment of any apparatus embodiment, a method or process embodiment, or even merely a variation of any element of these. Such terms can be substituted where desired to make explicit the implicitly broad coverage to which this disclosure is entitled.

    In addition, as to each term used it should be understood that unless its utilization in this application is inconsistent with such interpretation, common dictionary definitions should be understood as incorporated for each term and all definitions, alternative terms, and synonyms such as contained in at least one of a standard technical dictionary recognized by artisans and the Random House Webster's Unabridged Dictionary, latest edition are hereby incorporated by reference.

    Support should be understood to exist to the degree required under new matter laws— including but not limited to United States Patent Law 35 USC or other such laws - to permit the addition of any of the various dependencies or other elements presented under one independent claim or concept as dependencies or elements under any other independent claim or concept.

    Thus, unless the context requires otherwise, it should be understood that the term "compromise" or variations such as "comprises" or "comprising", are intended to imply the inclusion of a stated element or step or group of elements or steps but not the exclusion of any other element or step or group of elements or steps. The scope of the present invention is limited only by the scope of the following claims.

    Many modifications and variations will be apparent to those of ordinary skill in the art. The embodiment described and shown in the figures was chosen and described in order to best explain the principles of the invention, the practical application, and to enable others of ordinary skill in the art to understand the invention for various embodiments with various modifications as are suited to the particular use contemplated.

    Country of ref document: Kind code of ref document: Date of ref document: This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy.

    Background [] Cannabis contains more than compounds of which around 70 are considered as phytocannabinoids. Summary of the Embodiments [] This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unified sequential process that encapsulate a high concentration of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe, daily, long term and more efficacious cannabinoid therapy.

    Description of the Figures [] Figure 1 shows the average plasma THC concentrations during 4 hours after administration of 5. Detailed Description of the Disclosure [] Unless otherwise indicated, all numbers expressing quantities of ingredients, dimensions reaction conditions and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about".

    Phospholipids include natural occurring phospholipids like phosphatidylcholine sphingosine, gangliosides, and phytosphingosine and combinations thereof derived from soy and lecithin that are preferable for use in this disclosure and the synthetic phospholipids that include but are not limited to diacylglycerols, phosphatidic acids, phosphocholines, phosphoethanolamines, phosphoglycerols, [] The term "essential phospholipids" in the present disclosure refers to the highly purified extract of characteristic fatty acid composition of the phospholipids distinguished by their particular high content of polyunsaturated fatty acids, predominantly linoleic acid approx.

    This is especially relevant on the nanoscale where biomaterials function differently can introduce undesirable, adverse and sometimes toxic effects. Cannabinoid therapy [] Cannabinoid based medications have been intensely studied since the endogenous cannabinoid system was discovered two decades ago.

    The Endocannabinoid System regulates numerous fundamental physiological processes involving the CNS and autonomic nervous system, immune, endocrine, reproductive and cardiovascular activity. Imbalances in the Endocannabinoid System can produce impairments of various processes including neuroinflammation, immunomodulation and food control.

    The binding of the cannabinoid ligand to the receptor leads to a signaling cascade that either decreases or increases the activity of a particular enzyme to raise a receptor response above basal activity They target proteins that are usually transcription factors, proteins that bind DNA and promote the expression of certain genes within the cell that alter cellular communication.

    Cannabinoids Effects on Cell Membranes [] Cell membranes are primarily composed of a variety of lipids in the form of two asymmetric leaflets and functional proteins.

    Low Bioavailability of Oral and Intraoral Delivered Cannabinoids [] Cannabinoids are nearly insoluble in water but soluble in lipids, alcohols and other non-polar organic solvents. Safety Considerations of Cannabinoid Nanoparticles [] At the nanoscale, the physical and chemical properties of materials differ in fundamental ways from the properties of the atoms and molecules of bulk materials.

    Intraoral Sublingual Delivery of Nanoparticle Cannabinoids [] The absorption of the lipid nanoparticle drugs through the sublingual route is 3 to 10 times greater than the oral route and is only surpassed by hypodermic injection. During the auditory task, again these two compounds had opposite effects in the superior temporal cortex when subjects listened to speech and in the occipital cortex during visual processing [ Winton-Brown et al.

    Our group also assessed whether pretreatment with CBD could prevent the acute psychotic symptoms induced by dTHC when six healthy volunteers were administered dTHC intravenously on two occasions, after placebo or CBD pretreatment [ Bhattacharyya et al. Both animal and human studies indicate that CBD has anxiolytic properties. In fact in a recent double-blind study carried out on patients with generalized social anxiety disorder, it was found that relative to placebo, CBD significantly reduced subjective anxiety and its effect was related to its activity on limbic and paralimbic areas as shown by single photon emission computed tomography [ Crippa et al.

    CBD has also been proposed to have antipsychotic effects and is considered a potential antipsychotic medicine, particularly due its relatively low side-effect profile [ Zuardi et al. Another interesting compound of the plant, dtetrahydrocannabivarin dTHCV , a novel CB1R antagonist, also exerts potentially useful actions in the treatment of epilepsy and obesity [ Pertwee, ; Izzo et al.

    A review of this compound, along with dTHC and CBD by Pertwee suggests that plant extractions of d - 9-THCV produces its antiobesity effects more by increasing energy expenditure than by reducing food intake [ Pertwee, ]. The author also points out that a medicine such as dTHCV, by simultaneously blocking CB1Rs and activating CB2Rs, may have potential for the management of disorders such as chronic liver disease and obesity, particularly when these are associated with inflammation.

    However, the CBD content was found to be extremely low in more recent times. More recently, a meta-analysis to assess the potency of cannabis from to was carried out. From 21 case series covering a number of countries, a recent and consistent worldwide increase in cannabis potency was reported [ Cascini et al. These findings suggest that current trends for preferring higher THC content variants carry significant health risks, particularly to those who are susceptible to its harmful effects.

    Indeed, Morgan and colleagues carried out a study on current users, which included 66 daily and 54 recreational users, whose hair analyses revealed their THC and CBD amounts. The study found that higher THC levels in hair in daily users were associated with increased depression and anxiety, as well as poorer prose recall and source memory [ Morgan et al. However, higher CBD in hair was associated with lower psychosis-like symptoms and better recognition memory.

    In relation to people with psychosis, health risks are even higher with stronger variants of the plant. In a recent study of people with a first episode of psychosis, it was found that patients used higher-potency cannabis for longer durations and greater frequency compared with a healthy control group [ Di Forti et al.

    As the stronger variants have been taking over the street market, there has been a surge of interest in studying the links between cannabis use and mental health problems. The first to draw attention to such a link was a number of epidemiological studies and reviews, which pointed towards an association between the use of cannabis and the increased risk of developing a psychotic illness, in a dose-dependent manner [ Zammit et al. A psychotic outcome is not the only diagnostic category which has been associated with cannabis use.

    Symptoms of depression and anxiety commonly coexist with cannabis use and lead to diagnostic dilemmas [ Nunes et al. Cannabis use can induce such symptoms, as well as be used secondary to a primary depressive illness [ Dakwar et al. As the majority of the studies have had psychotic illness as an outcome, in this section we will mainly be focusing on this diagnostic category.

    This is important as the strong THC variants of cannabis use have been increasing steeply, as have concerns on cannabis-related health risks, particularly for young people [ Hall and Degenhardt, ; Potter et al. Recent epidemiological studies point towards a link between the use of cannabis and the development of a psychotic illness [ Zammit et al. Further evidence comes from a systematic review of longitudinal and population-based studies which show that cannabis use significantly increases the risk of development of a psychotic illness in a dose-dependent manner [ Moore et al.

    The clinical picture of transient psychosis can be indistinguishable from a frank acute psychosis with delusions and hallucinations, except for its short duration. Evidently there is considerable variation in the effects of cannabis on individuals. The biological basis of this variable sensitivity is yet unclear. There have been a number of studies exploring which groups are more vulnerable to developing a psychotic outcome as a result of cannabis use [ van Os et al.

    Findings so far indicate that the effect of cannabis use is much stronger in those with any predisposition for psychosis at baseline than in those without [ Henquet et al. Indeed, individuals with a predisposition to psychosis indicated by a positive family history of psychosis have been found to be particularly sensitive to the effects of cannabis [ McGuire et al. Another indicator for a higher psychosis risk is the presence of subclinical psychotic features and again such individuals have been affected by a higher risk of developing a psychotic illness [ Henquet et al.

    Furthermore those who are at ultra high risk for psychosis have been reported to be more sensitive to the psychotogenic effects of cannabis compared with users in the general population [ Peters et al.

    Because of the reported links between the schizotypal personality and schizophrenia, this type of personality disorder has come under scrutiny in examining the role of cannabis in producing psychotic symptoms.

    Indeed, it has been shown that people scoring high in schizotypy who use cannabis are more likely to have psychosis-like experiences at the time of use, together with unpleasant side effects [ Barkus et al. This study has been replicated and it has been confirmed that those with schizotypal personality disorder carry a higher risk of experiencing psychotic symptoms with cannabis use [ Stirling et al.

    Most recently, another study has provided further support for a strong association between early cannabis use and the development of schizophrenia spectrum disorder symptoms [ Anglin et al. The reported vulnerability factors mentioned here imply a strong genetic predisposition and there have been a number of studies looking particularly to specific genes which have been implicated in psychoses.

    The first such study was carried out by Caspi and colleagues [ Caspi et al. In this longitudinal study, a specific susceptibility gene which has been linked to schizophrenia and bipolar disorder, catechol-O-methyltransferase COMT , was examined in a representative birth cohort followed to adulthood.

    The study found that carriers of the COMT valine allele were most likely to exhibit psychotic symptoms and to develop schizophreniform disorder if they used cannabis before the age of However, the number of people carrying this allele was small in this study. Using a case-only design of people with schizophrenia, Zammit and colleagues re-examined this association but their findings did not support the different effects of cannabis use on schizophrenia according to variation in COMT [ Zammit et al.

    More recently, van Winkel and colleagues looked at the effects of recent cannabis use whilst examining single nucleotide polymorphisms in 42 candidate genes in patients with psychosis and their unaffected siblings [ van Winkel et al.

    The authors found that genetic variation in serine-threonine protein kinase AKT1 may mediate both short- and long-term effects on psychosis expression associated with cannabis use. Further support for the possible involvement of the AKT1 gene comes from our study with healthy volunteers.

    This study found that, during the encoding and recall conditions of the verbal memory task, the induction of psychotic symptoms by dTHC was correlated with the attenuated striatal and midbrain activation only in those who were G homozygotes of AKT1 and carriers of the 9-repeat allele dopamine transporter DAT1 [ Bhattacharyya et al. Apart from schizotypal personality, the vulnerability factors to the psychotogenic effects of cannabis require replication.

    It is clear that further work needs to be carried out to explore the biological mechanisms which determine the vulnerability towards a psychotic outcome. During the last decade, endocannabinoid research has been one of the fastest growing fields in psychopharmacology, opening ways to discover new medicines for a wide variety of health problems, ranging from metabolic disorders, to glaucoma and schizophrenia.

    The distribution of the endocannabinoid system in the brain is interesting as the very same brain areas are also implicated in psychoses, particularly in schizophrenia.

    Furthermore, complex and intricate involvement of this system with other neurotransmitters such as dopamine, GABA and glutamatergic systems may have implications for the development of a psychotic illness. Naturally, due to the recent and constant increase in the availability of higher THC content variants of cannabis around the world, there have been increasing concerns about the health risks, particularly for young people. However, cannabis affects people differently and therefore it is important to understand what makes someone more at risk and how they differ compared with those who do not develop psychotic illness.

    Here we have provided an overview of the available information on the risk factors which may make an individual more at risk, such as predisposition to psychosis, schizotypal personality and certain susceptibility genes. Finding groups who are vulnerable is particularly important so that they can be targeted for early preventative and therapeutic interventions.

    Such a search would also lead to the discovery of the biochemical mechanisms involved in cannabis and endocannabinoid research and ultimately to a better understanding of how the brain and the body functions.

    Thanks to Ethan Russo and Geoffrey W. Guy for providing the inspiration for Table 1. Also thanks to Dr Sanem Atakan for her help with the editing of the first draft. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest statement: The author declare no conflicts of interest in preparing this article. National Center for Biotechnology Information , U.

    Journal List Ther Adv Psychopharmacol v. Author information Copyright and License information Disclaimer. This article has been cited by other articles in PMC. Abstract Cannabis is a complex plant, with major compounds such as deltatetrahydrocannabinol and cannabidiol, which have opposing effects. Cannabis, deltatetrahydrocannabinol, cannabidiol, tetrahydrocannabivarin, endocannabinoids, individual sensitivity to cannabis.

    Introduction Cannabis is a complex plant with over chemical entities of which more than 60 of them are cannabinoid compounds, some of them with opposing effects. Brief history of the biochemistry of the cannabis plant Even though cannabis has been used and cultivated by mankind for at least years [ Li, ] our current knowledge on its pharmacological properties is based on studies which have taken place only since the end of the nineteenth century. Open in a separate window.

    Chemical Components of Cannabis

    Dec 11, Cannabis is rapidly becoming a commodity business, requiring differentiation and branding for lasting success. The Holy Grail of cannabis. Cannabis is a complex plant, with major compounds such as .. CBD also decreased the anxiety component of dTHC effects in such a way that the subjects. Mar 3, Cannabinoids are liposoluble. The active components of cannabis, whether THC or CBD, are dissolved only and exclusively in fats, oils and.



    Add Comment